Neos-Hidantoina en es it fr

Neos-Hidantoina Brand names, Neos-Hidantoina Analogs

Neos-Hidantoina Brand Names Mixture

  • Dilantin W Phenobarbital 15mg (Phenobarbital + Phenytoin Sodium)
  • Dilantin W Phenobarbital 30mg Cap (Phenobarbital + Phenytoin Sodium)

Neos-Hidantoina Chemical_Formula


Neos-Hidantoina RX_link

Neos-Hidantoina fda sheet

Neos-Hidantoina FDA

Neos-Hidantoina msds (material safety sheet)

Neos-Hidantoina MSDS

Neos-Hidantoina Synthesis Reference

Henze, U.S. Pat. 2,409,754 (1946)

Neos-Hidantoina Molecular Weight

252.268 g/mol

Neos-Hidantoina Melting Point

286 oC

Neos-Hidantoina H2O Solubility

32 mg/L

Neos-Hidantoina State


Neos-Hidantoina LogP


Neos-Hidantoina Dosage Forms

Capsule (extended release); Liquid; Solution; Suspension; Tablet

Neos-Hidantoina Indication

For the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.

Neos-Hidantoina Pharmacology

Phenytoin is an antiepileptic drug which can be useful in the treatment of epilepsy. The primary site of action appears to be the motor cortex where spread of seizure activity is inhibited. Phenytoin reduces the maximal activity of brain stem centers responsible for the tonic phase of tonic-clonic (grand mal) seizures. Phenytoin acts to damp the unwanted, runaway brain activity seen in seizure by reducing electrical conductance among brain cells. It lacks the sedation effects associated with phenobarbital. There are some indications that phenytoin has other effects, including anxiety control and mood stabilization, although it has never been approved for those purposes by the FDA.

Neos-Hidantoina Absorption

Bioavailability 70-100% oral, 24.4% for rectal and intravenous administration. Rapid rate of absorption with peak blood concentration expected in 1½ to 3 hours.

Neos-Hidantoina side effects and Toxicity

Oral, mouse: LD50 = 150 mg/kg; Oral, rat: LD50 = 1635 mg/kg. Symptoms of overdose include coma, difficulty in pronouncing words correctly, involuntary eye movement, lack of muscle coordination, low blood pressure, nausea, sluggishness, slurred speech, tremors, and vomiting.

Neos-Hidantoina Patient Information

Patients taking phenytoin should be advised of the importance of adhering strictly to the prescribed dosage regimen, and of informing the physician of any clinical condition in which it is not possible to take the drug orally as prescribed, eg, surgery, etc.

Patients should also be cautioned on the use of other drugs or alcoholic beverages without first seeking the physician's advice.

Patients should be instructed to call their physician if skin rash develops.

The importance of good dental hygiene should be stressed in order to minimize the development of gingival hyperplasia and its complications.

Do not use capsules which are discolored.

Neos-Hidantoina Organisms Affected

Humans and other mammals